1115.1000 -51.90 (-4.45%)
NSE Aug 01, 2025 15:31 PM
Volume: 103.7K
 

1115.10
-4.45%
ICICI Securities Limited
Tatva Chintan’s Q4FY23 revenue rose 26.4% YoY to Rs1.2bn as SDA revenue recovered to Rs0.5bn, up 41% YoY. However, gross profit margin dip of 400bps to 39.8% was disappointing (partly from a change in product mix) considering the company has guided for a sequential improvement in margins.
Tatva Chintan Pharma Chem Ltd. has gained 17.02% in the last 1 Month
More from Tatva Chintan Pharma Chem Ltd.
Recommended